Testing the Lumena — World’s 1st Aerosol-safe NIV Mask

In the process of testing the world’s first aerosol-safe non-invasive ventilation (NIV) mask, a freelance scientist from open talent platform Kolabtree has supported Israeli medical device manufacturer Inspir Labs. The freelancer, Dr. Nicholas Miceli, carried out a statistical analysis comparing the infection risk for those wearing the new mask against competitive products. Inspir Labs used this analysis to better understand the implications of different silicone and polycarbonate types, mask-face dynamics, and more.

Aerosol-generating procedures (AGPs) create large amounts of small droplets that remain buoyant in the air, which carry a severe risk of infection for patients and healthcare workers. Unlike respiratory droplets, aerosols are small enough to penetrate or circumnavigate most surgical masks. At the start of the pandemic, this risk meant that many hospitals refrained from giving patients non-invasive ventilation (NIV) for fear of infection, leading to more intubations as a result. To combat this, Labs designed an NIV mask that uses a pressure gradient to prevent aerosol emissions from being released into the environment.

“We saw how the pandemic exacerbated the risk caused by aerosol hazards — developing NIV technology that takes into consideration not only the patient, but also the medical staff was the obvious solution,” explained Nadav Nahmias, Chief Technology Officer at Inspir Labs. “During product development, we needed to compare the infection risk for various common viruses in both non-vented and medium-vented hospital wards to see how effective our mask would be. We needed to quantify this information so that we could analyze and present it when applying for regulatory approvals and presenting it to physicians.”

Aerosol-Safe Niv Mask

Inspir Labs posted the project on Kolabtree and was contacted by Dr. Nicholas Miceli, a freelance epidemiology expert. An associate professor of human resource management and healthcare management at Park University in Missouri, Nicholas was previously a researcher at the Ohio Department of Health and had also taught statistics and finite mathematics. This experience provided Nicholas with the necessary skills to carry out a statistical analysis for Inspir Labs, comparing the performance of the new aerosol-safe mask with competitive products.

“Inspir Labs provided me with a journal article that used a specific analytical method and requested that I replicate the analysis with the data provided,” explained Dr Miceli. “Working together with a colleague from Park University’s physics department, I found that the client’s mask performed better than the competition’s.”

Following this important statistical analysis, Inspir Labs progressed into sales processes and regulatory approvals. The mask has now received regulatory approval in Canada, Japan and Israel and is being used as an infection control device in multiple hospitals, keeping healthcare workers safe during AGPs.

Need a freelancer for your medical device project? Post your project for free https://www.kolabtree.com/create-project.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy